Comparing drug-coated balloons and cutting balloons for treating arteriovenous fistula stenosis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to compare the efficacy and safety of drug-coated balloons versus cutting balloons in treating venous stenosis of autologous arteriovenous fistulas. It will recruit 180 patients across multiple centers from June 2024 to December 2025, dividing them into two groups based on the treatment method. The study will assess primary patency rates, re-intervention rates, and major adverse events during the perioperative period to determine which balloon type is more effective. Participants will be monitored at 1, 3, 6, and 12 months post-operation.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Subjects aged between 18 and 75 years. Subjects possess a mature upper limb autologous arteriovenous fistula (AVF) and have undergone at least one hemodialysis session.

Target lesion must be located in the venous segment of the upper limb AVF. Doppler ultrasound confirms that the target lesion stenosis is ≥50%, accompanied by at least one of the following clinical manifestations: elevated venous pressure during dialysis, abnormal fistula signs, significant reduction in blood flow (\<200ml/min).

Guidewire and balloon successfully pass through the lesion and complete dilation. 6.Subjects or their legal representatives must understand the purpose of the trial, voluntarily participate in the clinical trial, and sign an informed consent form, while also being willing to adhere to the specific follow-up schedules set by this trial.

Exclusion Criteria:

Target lesion located in the arterial segment or anastomosis of the AVF. Target lesion located in the lower limb AVF. Subjects with previous stent implantation in the AVF. Patients diagnosed with symptomatic central venous occlusive disease: AVF flow reduction accompanied by swelling of the ipsilateral limb, chest, or facial area, with DSA confirmation of central venous occlusive disease.

Subjects with two or more target lesions in the AVF (when two stenoses are less than 3 cm apart, they are considered as one target lesion).

Subjects with acute thrombosis in the AVF or who have undergone AVF thrombolysis or thrombectomy within the past 30 days.

Subjects who have undergone or plan to undergo surgical intervention on the AVF within 30 days.

Subjects with AVF infection or concurrent systemic active infection. Subjects planning renal transplantation or switching to peritoneal dialysis within the next 12 months.

Subjects with diseases causing coagulopathy, such as thrombocytopenic purpura. Subjects undergoing immunotherapy or suspected/diagnosed with vasculitis. Subjects with allergies or contraindications to heparin or contrast agents. Subjects who are pregnant or breastfeeding. Subjects with a life expectancy of less than 12 months.

Where it's running

• First Affiliated Hospital of Zhengzhou University
  Zhengzhou, Henan, China Recruiting
• The Second Affiliated Hospital of Nanjing Medical University
  Nanjing, Jiangsu, China Recruiting
• Renji Hospital
  Shanghai, Shanghai Municipality, China Recruiting

Study contacts

• Principal investigator: Lan Zhang — Shanghai Jiao Tong University School of Medicine，Renji Hospital
• Study coordinator: RuZhou Cao
• Email: caorzh@126.com
• Phone: +86 18616752813

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• SelfWrap-Assisted Arteriovenous Fistulas for Chronic Kidney Disease

  This study is testing if a new wrap called SelfWrap can make it safer and more effective for people with chronic kidney disease to have a new arteriovenous fistula created.

  Recruiting at 28 sites VenoStent · Bullhead City, Arizona and 27 other locations · NCT06001827

• Apixaban to help arm fistulas mature in people with end-stage kidney disease

  This trial will try a short course of apixaban in adults with end-stage kidney disease getting a new arm arteriovenous fistula to see if it helps the fistula mature for hemodialysis.

  Recruiting Combined military hospital lahore · Lahore, Punjab Province · NCT07559942

• Single-needle distal return for long-term AV fistula care

  This trial tests a single-needle method that draws blood from your arm fistula and returns it through a foot or lower-leg vein to see if it reduces damage and the need for repeat procedures in adults on thrice-weekly hemodialysis.

  Recruiting Suzhou Municipal Hospital of Anhui Province · Suzhou, Anhui · NCT07372027

• Liquid embolic treatment for brain arteriovenous malformations

  This study will test a new liquid embolic agent against the Onyx system in adults (18–80) with brain arteriovenous malformations to see if it is as safe and effective.

  Recruiting MicroPort NeuroTech Co., Ltd. · Shanghai, Shanghai Municipality · NCT07314047

• Velocity pAVF system for creating dialysis fistulas through a small skin puncture

  This trial will test whether the minimally invasive Velocity pAVF system can create a dependable dialysis fistula in adults with kidney failure or those expected to need hemodialysis soon.

  Recruiting at 13 sites Venova Medical · Dothan, Alabama and 12 other locations · NCT07153939

• Comparing drug-coated balloons to plain balloons for treating AVF stenosis

  This study is testing if a special drug-coated balloon works better than a regular balloon for treating narrow spots in blood vessels for patients with arteriovenous fistula stenosis.

  Recruiting Phase 3 Singapore General Hospital · Singapore · NCT06553443

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.